Claims
- 1. An oligonucleotide 5 to 50 nucleotides in length which is complementary to at least a portion of an HCV genomic or messenger RNA, said oligonucleotide being hybridizable to said RNA and capable of inhibiting the function of said RNA.
- 2. The oligonucleotide of claim 1 wherein said RNA comprises at least a portion of the polyprotein translation initiation codon of an HCV RNA.
- 3. The oligonucleotide of claim 2 comprising SEQ ID NO: 6.
- 4. A composition comprising the oligonucleotide of claim 1 in a pharmaceutically acceptable carrier.
- 5. The composition of claim 4 further comprising interferon.
- 6. A phosphorothioate oligodeoxynucleotide having SEQ ID NO: 6 wherein every cytidine nucleotide is a 5-methylcytidine.
- 7. A composition comprising the oligonucleotide of claim 6 in a pharmaceutically acceptable carrier.
- 8. The composition of claim 7 further comprising interferon.
- 9. A method for inhibiting the activity of a Hepatitis C virus comprising contacting the virus or cells infected with the virus with an effective amount of the oligonucleotide of claim 1.
- 10. A method for inhibiting the activity of a Hepatitis C virus comprising contacting the virus or cells infected with the virus with an effective amount of the oligonucleotide of claim 6.
- 11. A method for treating an HCV-associated disease comprising contacting an animal suspected of having an HCV-associated disease, or tissues, cells or a bodily fluid from said animal, with a therapeutically effective amount of the oligonucleotide of claim 1.
- 12. The method of claim 11 wherein the HCV-associated disease is acute HCV infection, fulminant hepatitis, chronic active hepatitis, cirrhosis, or hepatocellular carcinoma.
- 13. A method for treating an HCV-associated disease comprising contacting an animal suspected of having an HCV-associated disease, or tissues, cells or a bodily fluid from said animal, with a therapeutically effective amount of the oligonucleotide of claim 6.
- 14. The method of claim 13 wherein the HCV-associated disease is acute HCV infection, fulminant hepatitis, chronic active hepatitis, cirrhosis, or hepatocellular carcinoma.
- 15. A method for preventing an HCV-associated disease comprising contacting an animal suspected of having been exposed to HCV, or cells, tissues or a bodily fluid from said animal, with a prophylactically effective amount of the oligonucleotide of claim 1.
- 16. The method of claim 15 wherein the HCV-associated disease is acute HCV infection, fulminant hepatitis, chronic active hepatitis, cirrhosis, or hepatocellular carcinoma.
- 17. A method for preventing an HCV-associated disease comprising contacting an animal suspected of having been exposed to HCV, or cells, tissues or a bodily fluid from said animal, with a prophylactically effective amount of the oligonucleotide of claim 6.
- 18. The method of claim 17 wherein the HCV-associated disease is acute HCV infection, fulminant hepatitis, chronic active hepatitis, cirrhosis, or hepatocellular carcinoma.
INTRODUCTION
[0001] This application is a continuation-in-part of U.S. Ser. No. 09/690,936 filed Oct. 18, 2000, which is a continuation of U.S. Ser. No. 08/988,321, filed Dec. 10, 1997, which is a continuation-in-part of U.S. Ser. No. 08/650,093, filed May 17, 1996, which is a continuation-in-part of U.S. Ser. No. 08/452,841, filed May 30, 1995, which in turn is a continuation-in-part of U.S. Ser. No. 08/397,220, filed Mar. 9, 1995, which is a continuation-in-part of U.S. Ser. No. 07/945,289, filed Sep. 10, 1992.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08988321 |
Dec 1997 |
US |
Child |
09690936 |
Oct 2000 |
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
09690936 |
Oct 2000 |
US |
Child |
09853409 |
May 2001 |
US |
Parent |
08650093 |
May 1996 |
US |
Child |
08988321 |
Dec 1997 |
US |
Parent |
08452841 |
May 1995 |
US |
Child |
08650093 |
May 1996 |
US |
Parent |
08397220 |
Mar 1995 |
US |
Child |
08452841 |
May 1995 |
US |
Parent |
07945289 |
Sep 1992 |
US |
Child |
PCT/JP93/01293 |
Sep 1993 |
US |